All News
Filter News
Found 92 articles
-
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
1/20/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has received a written response from the U.S. Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application for the treatment of MDD with BETR-001.
-
BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!
12/22/2021
BetterLife today announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), has signed an agreement with an European-based investor group to complete a non-brokered financing of up to US$5.0 million by way of private placement of Altum’s common shares.
-
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression
12/9/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has obtained the first set of positive data showing anti-depressant properties of its lead compound, 2-bromo-LSD (“TD-0148A”) in animal depression models, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University’s (Carleton) Department of Neuroscience.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!
12/3/2021
BetterLife Pharma Inc. is pleased to announce that Dr. Ahmad Doroudian will be participating in the H.C. Wainwright 2nd Annual Psychedelics Conference.
-
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
11/29/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo controlled trial.
-
Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2
10/12/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU ), is pleased to announce early positive in vitro results from Dr. Stephen Barr’s Laboratory at the state-of-the-art ImPaKT Facility at the Schulich School of Medicine & Dentistry, Western University, Ontario.
-
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
10/11/2021
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders
9/27/2021
BetterLife Pharma Inc. is pleased to announce it has applied for patent protection of new compositions of 2-bromo-LSD for its use in the treatment of cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.
-
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
9/22/2021
BetterLife Pharma Inc. announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc., and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phase 1-2 randomized placebo controlled in COVID-19 patients.
-
BetterLife to Present at the Emerging Growth Conference on September 15, 2021
9/13/2021
BetterLife Pharma Inc., an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce that it has been invited to present at the Emerging Growth Conference on September 15, 2021.
-
BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies
9/9/2021
BetterLife Pharma Inc., an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces an agreement with Laboratory of Dr. John McCorvy at the Medical College of Wisconsin for TD-0148A preclinical receptor binding studies.
-
BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2
8/25/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce initiation of in vitro studies of its recombinant human interferon alpha-2b (“rhIFN⍺2b” or “AP-003”) against the Delta variant of SARS-CoV-2.
-
BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile
7/27/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have obtained approval from the Instituto de Salud Publica de Chile to conduct their planned randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients.
-
BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety
7/22/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application with Dr. Argel Aguilar-Valles at Carleton University (“Carleton”) Department of Neuroscience by the Accelerate program at Mitacs for research into the anxiolytic potential of TD-010 in preclinical models of chronic anxiety and depression.
-
BetterLife to Present at the Emerging Growth Conference
7/19/2021
BetterLife Pharma Inc., an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, is pleased to announce that it has been invited to present at the Emerging Growth Conference on July 21, 2021.
-
Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19
7/15/2021
BetterLife Pharma Inc. is pleased to announce early positive in vitro results of its SARS-CoV-2 (“COVID-19”) anti-viral, recombinant human interferon alpha-2b (“rhIFN⍺2b” or “AP-003”), from the Dr. Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University (“UWO”). AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease.
-
BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies
6/24/2021
BetterLife Pharma Inc. is pleased to announce that a joint application to the Mitacs Accelerate program, in collaboration with Dr. Argel Aguilar-Valles at Carleton University Department of Neuroscience, was successfully funded for research into the anti-depressant effects of TD-0148A in preclinical models of chronic depression.